nAMD and DME: Novel Treatment Plans to Prioritize Real-World Visual Improvements
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Activity Description
Frequent intravitreal injections of anti-vascular endothelial growth factor (VEGF) therapies can significantly improve visual and anatomical outcomes for many patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, the requisite high number of treatments often leads to less-than-ideal results compared to outcomes reported in major clinical trials, largely due to the demanding treatment schedule. Adopting tailored treatment plans, along with the use of FDA-approved therapies that allow for longer intervals between injections, has shown promise in decreasing the need for frequent treatments while maintaining gains in visual acuity and anatomical outcomes. In this CE activity, experts in the field review practical strategies, methods, and protocols derived from real-world evidence to improve the treatment of nAMD and evaluate evidence-supported, durable treatment strategies that emphasize safety and aim to enhance vision for individuals with DME.
Target Audience
The intended audience for this activity is ophthalmologists and other healthcare professionals involved in the management of patients with nAMD and DME.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Apply practical strategies, methods, and protocols derived from real-world evidence to improve the treatment of nAMD.
- Incorporate evidence-based, durable treatment strategies that emphasize safety and aim to enhance vision for persons with DME.
Activity Chair
Sophie J. Bakri, MD
Chair, Department of Ophthalmology
Whitney and Betty MacMillan Professor of Ophthalmology in Honor of Robert R. Waller, MD
Mayo Clinic
Rochester, MN
Faculty
Durga Borkar, MD, MMCi
Assistant Professor of Ophthalmology
Duke University School of Medicine
Durham, NC
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, September 22, 2024, to September 21, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 of the 4 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Sophie J. Bakri, MD
Consultant: AbbVie, Adverum, Allergan, Amgen, Annexon, Apellis, Aviceda, Cholgene, EyePoint, iLumen, IVERIC bio, Genentech, Neurotech, Novartis, Ocular Therapeutix, Outlook, Pixium, Regenxbio, Rejuvitas, Re-Vana, Roche, VoxelCloud, Zeiss
Independent Research Contractor (paid to institution): Regenxbio
Durga Borkar, MD, MMCi
Consultant: AbbVie/Allergan, Alimera, Apellis, EyePoint, Genentech, IVERIC bio, ONL Therapeutics, Regeneron
Speaker Contracted by Ineligible Company: Astellas, IVERIC bio
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2024 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com